Clinical-stage phase II • Delivering natural gut hormones via novel “topical lingual” delivery platform. Novel topical lingual delivery technology leverages unexploited biological pathway “neural targeting via lingual activation” by application of micro-dose natural peptides to the tongue • Activates the satiety centers of the brain while avoiding nausea centers • Raising $35m to conduct OUS proof of concept studies with primary endpoint of total weight loss at 3 months in multiple placebo-controlled RCTs • Gila will deliver first PYY to market • Gila platform’s breakthrough risk-benefit profile enables new drug combinations and treatment targets.